Sun Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 6/6
Sun Pharmaceutical Industries has a total shareholder equity of ₹632.0B and total debt of ₹19.3B, which brings its debt-to-equity ratio to 3.1%. Its total assets and total liabilities are ₹794.4B and ₹162.4B respectively. Sun Pharmaceutical Industries's EBIT is ₹102.1B making its interest coverage ratio -37.3. It has cash and short-term investments of ₹148.3B.
Key information
3.1%
Debt to equity ratio
₹19.28b
Debt
| Interest coverage ratio | -37.3x |
| Cash | ₹148.33b |
| Equity | ₹631.97b |
| Total liabilities | ₹162.44b |
| Total assets | ₹794.41b |
Recent financial health updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13
We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Recent updates
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jan 19Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Dec 27Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Nov 04Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Oct 21Calculating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Sep 27Financial Position Analysis
Short Term Liabilities: SUNPHARMA's short term assets (₹393.5B) exceed its short term liabilities (₹150.2B).
Long Term Liabilities: SUNPHARMA's short term assets (₹393.5B) exceed its long term liabilities (₹12.2B).
Debt to Equity History and Analysis
Debt Level: SUNPHARMA has more cash than its total debt.
Reducing Debt: SUNPHARMA's debt to equity ratio has reduced from 23.6% to 3.1% over the past 5 years.
Debt Coverage: SUNPHARMA's debt is well covered by operating cash flow (602.5%).
Interest Coverage: SUNPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.